Carolwood Pacific Railroad

RxSight, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on:

Wednesday, February 28, 2024

MCI Inc., Shareholder, LDD, Investment, Growth, Sale, Annual general meeting, LAL, Patient, Carolwood Pacific Railroad, Video game

Revenue growth was driven by a 52% increase in LDD revenue and a 98% increase in LAL revenue compared to the fourth quarter of 2022.

Key Points:

Revenue growth was driven by a 52% increase in LDD revenue and a 98% increase in LAL revenue compared to the fourth quarter of 2022.
Gross profit for the fourth quarter of 2023 was $17.7 million or 62% of revenue, an increase of $10.2 million or 138% compared to gross profit of $7.4 million or 46% of revenue for the fourth quarter of 2022.
Total operating expenses for the fourth quarter of 2023 were $28.5 million, a 27% increase from $22.4 million in the fourth quarter of 2022, reflecting the company’s ongoing investments to grow its LDD installed base and support increased LAL procedure volumes.
On Wednesday, February 28, 2024, at 1:30 p.m. Pacific Time, the company will host a conference call to discuss its fourth quarter 2023 and full year 2023 financial results.

Lamoille Health Partners Achieves Top Honors in Clinical Quality Leadership Awards by HRSA

Retrieved on:

Friday, November 17, 2023

Health equity, HIT, Collection, CHQR, Patient, HRSA, PCMH, Carolwood Pacific Railroad, Human services, Look-alike, St. Peter's Health Partners, Nursing, Health

MORRISVILLE, Vt., Nov. 17, 2023 /PRNewswire/ -- Lamoille Health Partners has been recognized by the Health Resources and Services Administration (HRSA) as a National Health Center Quality Leader, ranking among the top 20% of US health centers for best overall clinical performance in 2023. This new Silver Level status validates Lamoille Health Partners' dedication to quality care and access to members of its communities, increasing from Bronze level in 2022.

Key Points:

Lamoille Health Partners now ranks in the top 20% of US Health Centers for quality outcomes.
MORRISVILLE, Vt., Nov. 17, 2023 /PRNewswire/ -- Lamoille Health Partners has been recognized by the Health Resources and Services Administration (HRSA) as a National Health Center Quality Leader, ranking among the top 20% of US health centers for best overall clinical performance in 2023.
This new Silver Level status validates Lamoille Health Partners' dedication to quality care and access to members of its communities, increasing from Bronze level in 2022.
The Health Resources & Services Administration (HRSA) recognizes Health Center Program awardees and look-alikes (LALs) that have made notable quality improvement achievements in the areas of access, quality, health equity, and health information technology through its Community Health Quality Recognition (CHQR) badges.

RxSight, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on:

Monday, March 6, 2023

Provided 2023 gross margin guidance range of 52% to 54%, representing an implied increase of 19% to 24% compared to 2022.

Key Points:

Provided 2023 gross margin guidance range of 52% to 54%, representing an implied increase of 19% to 24% compared to 2022.
Gross profit for the fourth quarter of 2022 was $7.4 million or 46.1% of revenue, an increase of $4.5 million or 159% compared to gross profit of $2.9 million or 34.0% of revenue for the fourth quarter of 2021.
Total operating expenses for the fourth quarter of 2022 were $22.4 million, a 28% increase from $17.5 million in the fourth quarter of 2021.
On Monday, March 6, 2023, at 1:30 p.m. Pacific Time, the company will host a conference call to discuss its fourth quarter 2022 and fiscal year 2022 financial results.

RxSight, Inc. Reports Fourth Quarter and Fiscal Year 2021 Financial Results

Retrieved on:

Tuesday, March 8, 2022

In the fourth quarter of 2021, total revenue was $8.4 million, an increase of 71% compared to the fourth quarter of 2020 and 46% growth over the prior quarter ended September 30, 2021.

Key Points:

In the fourth quarter of 2021, total revenue was $8.4 million, an increase of 71% compared to the fourth quarter of 2020 and 46% growth over the prior quarter ended September 30, 2021.
Gross profit for the fourth quarter of 2021 was $2.9 million, or 34% of revenue compared to gross profit of $1.4 million, or 28% for the fourth quarter of 2020.
Total operating expenses for the fourth quarter of 2021 were $17.5 million, an 81% increase from $9.7 million in the fourth quarter of 2020.
On Tuesday, March 8, 2022, at 1:30 p.m. Pacific Time, the company will host a conference call to discuss its fourth quarter and fiscal year 2021 financial results.

RxSight Reports Third Quarter 2021 Financial Results

Retrieved on:

Wednesday, November 10, 2021

ALISO VIEJO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today reported financial results for the three months ended September 30, 2021.

Key Points:

ALISO VIEJO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today reported financial results for the three months ended September 30, 2021.
In the third quarter of 2021, total revenue was $5.8 million, an increase of 39% compared to the third quarter of 2020 and 18% growth over the prior quarter ended June 30, 2021.
Total operating expenses for the third quarter of 2021 were $14.5 million, a 50% increase from $9.6 million in the third quarter of 2020.
On Wednesday, November 10, 2021, at 1:30 p.m. Pacific Time, the company will host a conference call to discuss its third quarter 2021 financial results.